首页 > 最新文献

PLoS Medicine最新文献

英文 中文
Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act. 生物仿制药法案》通过十年后,美国生物制剂系统知识产权信息匮乏。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-25 DOI: 10.1371/journal.pmed.1004381
Robin Feldman
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
在这篇《政策论坛》文章中,罗宾-费尔德曼(Robin Feldman)讨论了现行立法是如何造成美国生物药专利信息不足的。
{"title":"Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.","authors":"Robin Feldman","doi":"10.1371/journal.pmed.1004381","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004381","url":null,"abstract":"In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub. 每年接种重新配制的 COVID-19 疫苗的潜在影响:美国 COVID-19 情景建模中心的经验教训。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-17 DOI: 10.1371/journal.pmed.1004387
Sung-Mok Jung, Sara L Loo, E. Howerton, L. Contamin, Clair Smith, Erica C Carcelén, Katie Yan, Samantha J Bents, J. Levander, J. Espino, J. Lemaitre, Koji Sato, Clif McKee, Alison L Hill, Matteo Chinazzi, Jessica T. Davis, K. Mu, A. Vespignani, Erik T. Rosenstrom, Sebastian A Rodriguez-Cartes, Julie S. Ivy, Maria E. Mayorga, Julie L. Swann, G. España, S. Cavany, Sean M. Moore, T. A. Perkins, Shi Chen, Rajib Paul, Daniel Janies, J. Thill, A. Srivastava, Majd Al Aawar, Kaiming Bi, Shraddha Ramdas Bandekar, A. Bouchnita, S. Fox, L. A. Meyers, P. Porebski, S. Venkatramanan, A. Adiga, Benjamin Hurt, B. Klahn, J. Outten, Jiangzhuo Chen, H. Mortveit, Amanda Wilson, Stefan Hoops, P. Bhattacharya, D. Machi, Anil Vullikanti, B. Lewis, M. Marathe, Harry Hochheiser, Michael C. Runge, Katriona Shea, S. Truelove, Cécile Viboud, J. Lessler
BACKGROUNDCoronavirus Disease 2019 (COVID-19) continues to cause significant hospitalizations and deaths in the United States. Its continued burden and the impact of annually reformulated vaccines remain unclear. Here, we present projections of COVID-19 hospitalizations and deaths in the United States for the next 2 years under 2 plausible assumptions about immune escape (20% per year and 50% per year) and 3 possible CDC recommendations for the use of annually reformulated vaccines (no recommendation, vaccination for those aged 65 years and over, vaccination for all eligible age groups based on FDA approval).METHODS AND FINDINGSThe COVID-19 Scenario Modeling Hub solicited projections of COVID-19 hospitalization and deaths between April 15, 2023 and April 15, 2025 under 6 scenarios representing the intersection of considered levels of immune escape and vaccination. Annually reformulated vaccines are assumed to be 65% effective against symptomatic infection with strains circulating on June 15 of each year and to become available on September 1. Age- and state-specific coverage in recommended groups was assumed to match that seen for the first (fall 2021) COVID-19 booster. State and national projections from 8 modeling teams were ensembled to produce projections for each scenario and expected reductions in disease outcomes due to vaccination over the projection period. From April 15, 2023 to April 15, 2025, COVID-19 is projected to cause annual epidemics peaking November to January. In the most pessimistic scenario (high immune escape, no vaccination recommendation), we project 2.1 million (90% projection interval (PI) [1,438,000, 4,270,000]) hospitalizations and 209,000 (90% PI [139,000, 461,000]) deaths, exceeding pre-pandemic mortality of influenza and pneumonia. In high immune escape scenarios, vaccination of those aged 65+ results in 230,000 (95% confidence interval (CI) [104,000, 355,000]) fewer hospitalizations and 33,000 (95% CI [12,000, 54,000]) fewer deaths, while vaccination of all eligible individuals results in 431,000 (95% CI: 264,000-598,000) fewer hospitalizations and 49,000 (95% CI [29,000, 69,000]) fewer deaths.CONCLUSIONSCOVID-19 is projected to be a significant public health threat over the coming 2 years. Broad vaccination has the potential to substantially reduce the burden of this disease, saving tens of thousands of lives each year.
背景科罗纳病毒病 2019(COVID-19)继续在美国造成大量住院和死亡病例。其持续负担和每年重新配制疫苗的影响仍不清楚。在此,我们提出了在 2 种可信的免疫逃逸假设(每年 20% 和每年 50%)和疾病预防控制中心对使用每年重新配制的疫苗的 3 种可能建议(无建议、65 岁及以上人群接种疫苗、根据 FDA 批准所有符合条件的年龄组接种疫苗)下未来 2 年美国 COVID-19 住院人数和死亡人数的预测。方法和结果:COVID-19 情景建模中心征集了 2023 年 4 月 15 日至 2025 年 4 月 15 日期间在 6 种情景下 COVID-19 的住院和死亡预测,这 6 种情景代表了所考虑的免疫逃逸和疫苗接种水平的交叉点。假定每年重新配制的疫苗对每年 6 月 15 日流行毒株的无症状感染有效率为 65%,并于 9 月 1 日上市。假定推荐人群的特定年龄和州覆盖率与第一次(2021 年秋季)COVID-19 强化接种的覆盖率一致。8 个建模团队对各州和全国的预测结果进行了汇总,以得出每种情景的预测结果以及在预测期内因接种疫苗而导致的疾病结果的预期减少量。据预测,从 2023 年 4 月 15 日到 2025 年 4 月 15 日,COVID-19 将导致每年 11 月到次年 1 月达到流行高峰。在最悲观的情况下(高免疫逃逸,不建议接种疫苗),我们预计将有 210 万人(90% 预测区间 (PI) [143.8 万,427 万])住院,20.9 万人(90% 预测区间 (PI) [13.9 万,46.1 万])死亡,超过流感和肺炎流行前的死亡率。在高免疫逃逸情景下,为 65 岁以上人群接种疫苗可减少 230,000 例(95% 置信区间 [104,000, 355,000] )住院病例和 33,000 例(95% 置信区间 [12,000, 54,000] )死亡病例,而为所有符合条件的人接种疫苗可减少 431,000 例(95% 置信区间:264,000-598,000)住院病例和 49,000 例(95% 置信区间 [29,000, 69,000] )死亡病例。结论COVID-19 预计将在未来两年内对公共健康构成重大威胁。广泛接种疫苗有可能大大减轻这种疾病的负担,每年挽救数万人的生命。
{"title":"Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.","authors":"Sung-Mok Jung, Sara L Loo, E. Howerton, L. Contamin, Clair Smith, Erica C Carcelén, Katie Yan, Samantha J Bents, J. Levander, J. Espino, J. Lemaitre, Koji Sato, Clif McKee, Alison L Hill, Matteo Chinazzi, Jessica T. Davis, K. Mu, A. Vespignani, Erik T. Rosenstrom, Sebastian A Rodriguez-Cartes, Julie S. Ivy, Maria E. Mayorga, Julie L. Swann, G. España, S. Cavany, Sean M. Moore, T. A. Perkins, Shi Chen, Rajib Paul, Daniel Janies, J. Thill, A. Srivastava, Majd Al Aawar, Kaiming Bi, Shraddha Ramdas Bandekar, A. Bouchnita, S. Fox, L. A. Meyers, P. Porebski, S. Venkatramanan, A. Adiga, Benjamin Hurt, B. Klahn, J. Outten, Jiangzhuo Chen, H. Mortveit, Amanda Wilson, Stefan Hoops, P. Bhattacharya, D. Machi, Anil Vullikanti, B. Lewis, M. Marathe, Harry Hochheiser, Michael C. Runge, Katriona Shea, S. Truelove, Cécile Viboud, J. Lessler","doi":"10.1371/journal.pmed.1004387","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004387","url":null,"abstract":"BACKGROUND\u0000Coronavirus Disease 2019 (COVID-19) continues to cause significant hospitalizations and deaths in the United States. Its continued burden and the impact of annually reformulated vaccines remain unclear. Here, we present projections of COVID-19 hospitalizations and deaths in the United States for the next 2 years under 2 plausible assumptions about immune escape (20% per year and 50% per year) and 3 possible CDC recommendations for the use of annually reformulated vaccines (no recommendation, vaccination for those aged 65 years and over, vaccination for all eligible age groups based on FDA approval).\u0000\u0000\u0000METHODS AND FINDINGS\u0000The COVID-19 Scenario Modeling Hub solicited projections of COVID-19 hospitalization and deaths between April 15, 2023 and April 15, 2025 under 6 scenarios representing the intersection of considered levels of immune escape and vaccination. Annually reformulated vaccines are assumed to be 65% effective against symptomatic infection with strains circulating on June 15 of each year and to become available on September 1. Age- and state-specific coverage in recommended groups was assumed to match that seen for the first (fall 2021) COVID-19 booster. State and national projections from 8 modeling teams were ensembled to produce projections for each scenario and expected reductions in disease outcomes due to vaccination over the projection period. From April 15, 2023 to April 15, 2025, COVID-19 is projected to cause annual epidemics peaking November to January. In the most pessimistic scenario (high immune escape, no vaccination recommendation), we project 2.1 million (90% projection interval (PI) [1,438,000, 4,270,000]) hospitalizations and 209,000 (90% PI [139,000, 461,000]) deaths, exceeding pre-pandemic mortality of influenza and pneumonia. In high immune escape scenarios, vaccination of those aged 65+ results in 230,000 (95% confidence interval (CI) [104,000, 355,000]) fewer hospitalizations and 33,000 (95% CI [12,000, 54,000]) fewer deaths, while vaccination of all eligible individuals results in 431,000 (95% CI: 264,000-598,000) fewer hospitalizations and 49,000 (95% CI [29,000, 69,000]) fewer deaths.\u0000\u0000\u0000CONCLUSIONS\u0000COVID-19 is projected to be a significant public health threat over the coming 2 years. Broad vaccination has the potential to substantially reduce the burden of this disease, saving tens of thousands of lives each year.","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140692849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixed progress in global tobacco control. 全球烟草控制进展参差不齐。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-16 DOI: 10.1371/journal.pmed.1004392
Coral E Gartner, Wayne D Hall
{"title":"Mixed progress in global tobacco control.","authors":"Coral E Gartner, Wayne D Hall","doi":"10.1371/journal.pmed.1004392","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004392","url":null,"abstract":"","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
More research is needed on how to prevent vaping among young people. 需要对如何防止青少年吸食毒品进行更多的研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-15 DOI: 10.1371/journal.pmed.1004391
Coral E Gartner, Wayne D Hall
{"title":"More research is needed on how to prevent vaping among young people.","authors":"Coral E Gartner, Wayne D Hall","doi":"10.1371/journal.pmed.1004391","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004391","url":null,"abstract":"","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140699971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Climate change: A driver of increasing vector-borne disease transmission in non-endemic areas. 气候变化:非流行病地区病媒传播疾病增加的驱动因素。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-04 eCollection Date: 2024-04-01 DOI: 10.1371/journal.pmed.1004382
Shlomit Paz

In this Perspective, Shlomit Paz discusses the link between climate change and transmission of vector-borne diseases in non-endemic areas.

在本视角中,什洛米特-帕兹(Shlomit Paz)讨论了气候变化与非流行病地区病媒传播疾病之间的联系。
{"title":"Climate change: A driver of increasing vector-borne disease transmission in non-endemic areas.","authors":"Shlomit Paz","doi":"10.1371/journal.pmed.1004382","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004382","url":null,"abstract":"<p><p>In this Perspective, Shlomit Paz discusses the link between climate change and transmission of vector-borne diseases in non-endemic areas.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel electronic health record-based, machine-learning model to predict severe hypoglycemia leading to hospitalizations in older adults with diabetes: A territory-wide cohort and modeling study 基于电子健康记录的新型机器学习模型,用于预测导致老年糖尿病患者住院的严重低血糖症:全境队列和建模研究
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.1371/journal.pmed.1004369
M. Shi, A. Yang, E. Lau, A. Luk, Ronald C W Ma, Alice P S Kong, Raymond S M Wong, Jones C M Chan, Juliana C N Chan, Elaine Chow
Background Older adults with diabetes are at high risk of severe hypoglycemia (SH). Many machine-learning (ML) models predict short-term hypoglycemia are not specific for older adults and show poor precision-recall. We aimed to develop a multidimensional, electronic health record (EHR)-based ML model to predict one-year risk of SH requiring hospitalization in older adults with diabetes. Methods and findings We adopted a case-control design for a retrospective territory-wide cohort of 1,456,618 records from 364,863 unique older adults (age ≥65 years) with diabetes and at least 1 Hong Kong Hospital Authority attendance from 2013 to 2018. We used 258 predictors including demographics, admissions, diagnoses, medications, and routine laboratory tests in a one-year period to predict SH events requiring hospitalization in the following 12 months. The cohort was randomly split into training, testing, and internal validation sets in a 7:2:1 ratio. Six ML algorithms were evaluated including logistic-regression, random forest, gradient boost machine, deep neural network (DNN), XGBoost, and Rulefit. We tested our model in a temporal validation cohort in the Hong Kong Diabetes Register with predictors defined in 2018 and outcome events defined in 2019. Predictive performance was assessed using area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC) statistics, and positive predictive value (PPV). We identified 11,128 SH events requiring hospitalization during the observation periods. The XGBoost model yielded the best performance (AUROC = 0.978 [95% CI 0.972 to 0.984]; AUPRC = 0.670 [95% CI 0.652 to 0.688]; PPV = 0.721 [95% CI 0.703 to 0.739]). This was superior to an 11-variable conventional logistic-regression model comprised of age, sex, history of SH, hypertension, blood glucose, kidney function measurements, and use of oral glucose-lowering drugs (GLDs) (AUROC = 0.906; AUPRC = 0.085; PPV = 0.468). Top impactful predictors included non-use of lipid-regulating drugs, in-patient admission, urgent emergency triage, insulin use, and history of SH. External validation in the HKDR cohort yielded AUROC of 0.856 [95% CI 0.838 to 0.873]. Main limitations of this study included limited transportability of the model and lack of geographically independent validation. Conclusions Our novel-ML model demonstrated good discrimination and high precision in predicting one-year risk of SH requiring hospitalization. This may be integrated into EHR decision support systems for preemptive intervention in older adults at highest risk.
背景 老年人糖尿病患者发生严重低血糖症(SH)的风险很高。许多预测短期低血糖症的机器学习(ML)模型对老年人并不具有特异性,其精确度和召回率也很低。我们的目标是开发一种基于电子健康记录(EHR)的多维 ML 模型,用于预测患有糖尿病的老年人一年内需要住院治疗的 SH 风险。方法和结果 我们采用了病例对照设计,从2013年到2018年,对364863名患有糖尿病且至少在香港医院管理局就诊过一次的老年人(年龄≥65岁)的145618份记录进行了全港范围的回顾性队列研究。我们使用了 258 个预测因子,包括一年内的人口统计学、入院情况、诊断、药物和常规实验室检查,来预测随后 12 个月内需要住院治疗的 SH 事件。队列按 7:2:1 的比例随机分为训练集、测试集和内部验证集。我们评估了六种 ML 算法,包括逻辑回归、随机森林、梯度提升机、深度神经网络 (DNN)、XGBoost 和 Rulefit。我们在香港糖尿病登记册的时间验证队列中测试了我们的模型,预测因子定义于 2018 年,结果事件定义于 2019 年。预测性能采用接收者操作特征曲线下面积(AUROC)、精确度-召回曲线下面积(AUPRC)统计和阳性预测值(PPV)进行评估。在观察期间,我们共发现了 11128 例需要住院治疗的 SH 事件。XGBoost 模型的性能最佳(AUROC = 0.978 [95% CI 0.972 to 0.984];AUPRC = 0.670 [95% CI 0.652 to 0.688];PPV = 0.721 [95% CI 0.703 to 0.739])。这优于由年龄、性别、SH 病史、高血压、血糖、肾功能测量值和口服降糖药 (GLD) 使用情况组成的 11 变量传统逻辑回归模型(AUROC = 0.906;AUPRC = 0.085;PPV = 0.468)。影响最大的预测因素包括未使用调脂药物、住院、紧急分诊、使用胰岛素和有 SH 病史。HKDR队列的外部验证得出的AUROC为0.856 [95% CI 0.838 to 0.873]。本研究的主要局限性包括模型的可移动性有限以及缺乏独立的地域验证。结论 我们的新型 ML 模型在预测需要住院治疗的 SH 一年期风险方面具有良好的区分度和较高的精确度。该模型可集成到电子病历决策支持系统中,对高风险老年人进行先期干预。
{"title":"A novel electronic health record-based, machine-learning model to predict severe hypoglycemia leading to hospitalizations in older adults with diabetes: A territory-wide cohort and modeling study","authors":"M. Shi, A. Yang, E. Lau, A. Luk, Ronald C W Ma, Alice P S Kong, Raymond S M Wong, Jones C M Chan, Juliana C N Chan, Elaine Chow","doi":"10.1371/journal.pmed.1004369","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004369","url":null,"abstract":"Background Older adults with diabetes are at high risk of severe hypoglycemia (SH). Many machine-learning (ML) models predict short-term hypoglycemia are not specific for older adults and show poor precision-recall. We aimed to develop a multidimensional, electronic health record (EHR)-based ML model to predict one-year risk of SH requiring hospitalization in older adults with diabetes. Methods and findings We adopted a case-control design for a retrospective territory-wide cohort of 1,456,618 records from 364,863 unique older adults (age ≥65 years) with diabetes and at least 1 Hong Kong Hospital Authority attendance from 2013 to 2018. We used 258 predictors including demographics, admissions, diagnoses, medications, and routine laboratory tests in a one-year period to predict SH events requiring hospitalization in the following 12 months. The cohort was randomly split into training, testing, and internal validation sets in a 7:2:1 ratio. Six ML algorithms were evaluated including logistic-regression, random forest, gradient boost machine, deep neural network (DNN), XGBoost, and Rulefit. We tested our model in a temporal validation cohort in the Hong Kong Diabetes Register with predictors defined in 2018 and outcome events defined in 2019. Predictive performance was assessed using area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC) statistics, and positive predictive value (PPV). We identified 11,128 SH events requiring hospitalization during the observation periods. The XGBoost model yielded the best performance (AUROC = 0.978 [95% CI 0.972 to 0.984]; AUPRC = 0.670 [95% CI 0.652 to 0.688]; PPV = 0.721 [95% CI 0.703 to 0.739]). This was superior to an 11-variable conventional logistic-regression model comprised of age, sex, history of SH, hypertension, blood glucose, kidney function measurements, and use of oral glucose-lowering drugs (GLDs) (AUROC = 0.906; AUPRC = 0.085; PPV = 0.468). Top impactful predictors included non-use of lipid-regulating drugs, in-patient admission, urgent emergency triage, insulin use, and history of SH. External validation in the HKDR cohort yielded AUROC of 0.856 [95% CI 0.838 to 0.873]. Main limitations of this study included limited transportability of the model and lack of geographically independent validation. Conclusions Our novel-ML model demonstrated good discrimination and high precision in predicting one-year risk of SH requiring hospitalization. This may be integrated into EHR decision support systems for preemptive intervention in older adults at highest risk.","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140761715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term variations of urban–Rural disparities in infectious disease burden of over 8.44 million children, adolescents, and youth in China from 2013 to 2021: An observational study 2013-2021年中国超过844万儿童、青少年传染病负担城乡差异的长期变化:一项观察性研究
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.1371/journal.pmed.1004374
Li Chen, Yi Xing, Yi Zhang, Junqing Xie, Binbin Su, Jianuo Jiang, M. Geng, Xiang Ren, Tongjun Guo, W. Yuan, Qi Ma, Manman Chen, M. Cui, Jieyu Liu, Yi Song, Liping Wang, Yanhui Dong, Jun Ma
Background An accelerated epidemiological transition, spurred by economic development and urbanization, has led to a rapid transformation of the disease spectrum. However, this transition has resulted in a divergent change in the burden of infectious diseases between urban and rural areas. The objective of our study was to evaluate the long-term urban–rural disparities in infectious diseases among children, adolescents, and youths in China, while also examining the specific diseases driving these disparities. Methods and findings This observational study examined data on 43 notifiable infectious diseases from 8,442,956 cases from individuals aged 4 to 24 years, with 4,487,043 cases in urban areas and 3,955,913 in rural areas. The data from 2013 to 2021 were obtained from China’s Notifiable Infectious Disease Surveillance System. The 43 infectious diseases were categorized into 7 categories: vaccine-preventable, bacterial, gastrointestinal and enterovirus, sexually transmitted and bloodborne, vectorborne, zoonotic, and quarantinable diseases. The calculation of infectious disease incidence was stratified by urban and rural areas. We used the index of incidence rate ratio (IRR), calculated by dividing the urban incidence rate by the rural incidence rate for each disease category, to assess the urban–rural disparity. During the nine-year study period, most notifiable infectious diseases in both urban and rural areas exhibited either a decreased or stable pattern. However, a significant and progressively widening urban–rural disparity in notifiable infectious diseases was observed. Children, adolescents, and youths in urban areas experienced a higher average yearly incidence compared to their rural counterparts, with rates of 439 per 100,000 compared to 211 per 100,000, respectively (IRR: 2.078, 95% CI [2.075, 2.081]; p < 0.001). From 2013 to 2021, this disparity was primarily driven by higher incidences of pertussis (IRR: 1.782, 95% CI [1.705, 1.862]; p < 0.001) and seasonal influenza (IRR: 3.213, 95% CI [3.205, 3.220]; p < 0.001) among vaccine-preventable diseases, tuberculosis (IRR: 1.011, 95% CI [1.006, 1.015]; p < 0.001), and scarlet fever (IRR: 2.942, 95% CI [2.918, 2.966]; p < 0.001) among bacterial diseases, infectious diarrhea (IRR: 1.932, 95% CI [1.924, 1.939]; p < 0.001), and hand, foot, and mouth disease (IRR: 2.501, 95% CI [2.491, 2.510]; p < 0.001) among gastrointestinal and enterovirus diseases, dengue (IRR: 11.952, 95% CI [11.313, 12.628]; p < 0.001) among vectorborne diseases, and 4 sexually transmitted and bloodborne diseases (syphilis: IRR 1.743, 95% CI [1.731, 1.755], p < 0.001; gonorrhea: IRR 2.658, 95% CI [2.635, 2.682], p < 0.001; HIV/AIDS: IRR 2.269, 95% CI [2.239, 2.299], p < 0.001; hepatitis C: IRR 1.540, 95% CI [1.506, 1.575], p < 0.001), but was partially offset by lower incidences of most zoonotic and quarantinable diseases in urban areas (for example, brucellosis among zoonotic: IRR 0.516, 95% CI [0.498, 0.534], p < 0.00
背景 在经济发展和城市化的推动下,流行病学加速转型,导致疾病谱迅速变化。然而,这种转型也导致了城乡之间传染病负担的不同变化。我们的研究旨在评估中国儿童、少年和青年传染病的长期城乡差异,同时研究造成这些差异的特定疾病。方法和结果 本观察性研究从 8,442,956 例 4 至 24 岁人群中收集了 43 种应报告传染病的数据,其中城市地区 4,487,043 例,农村地区 3,955,913 例。2013 年至 2021 年的数据来自中国应报传染病监测系统。43 种传染病分为 7 类:疫苗可预防疾病、细菌性疾病、胃肠道和肠道病毒性疾病、性传播和血液传播疾病、病媒性疾病、人畜共患病和检疫性疾病。传染病发病率的计算按城市和农村地区进行分层。我们使用发病率比指数(IRR)来评估城乡差异,该指数是用每类疾病的城市发病率除以农村发病率计算得出的。在九年的研究期间,城市和农村地区的大多数应报告传染病都呈现出下降或稳定的模式。但是,在应报告的传染病中,城乡差异明显且逐渐扩大。城市儿童、少年和青年的年平均发病率高于农村儿童、少年和青年,分别为每 10 万人 439 例和每 10 万人 211 例(IRR:2.078,95% CI [2.075,2.081];P <0.001)。从 2013 年到 2021 年,这种差异主要是由于百日咳(IRR:1.782,95% CI [1.705,1.862];p <0.001)和季节性流感(IRR:3.213,95% CI [3.205,3.220];p <0.001)发病率较高造成的。在疫苗可预防疾病中,结核病(IRR:1.011,95% CI [1.006,1.015];P < 0.001)和猩红热(IRR:2.942,95% CI [2.918,2.966];P < 0.001)、细菌性疾病中的感染性腹泻(IRR:1.932,95% CI [1.924,1.939];P < 0.001)和手足口病(IRR:2.501,95% CI [2.491,2.510];P < 0.001)、病媒传播疾病中的登革热(IRR:11.952,95% CI [11.313,12.628];P < 0.001)以及 4 种性传播和血液传播疾病(梅毒:梅毒:IRR 1.743,95% CI [1.731,1.755],P <0.001;淋病:IRR 2.658,95% CI [2.635,2.682],P <0.001;艾滋病毒/艾滋病:IRR为2.269,95% CI [2.239,2.299],P <0.001;丙型肝炎IRR为1.540,95% CI [1.506,1.575],p <0.001),但城市地区大多数人畜共患病和检疫性疾病发病率较低部分抵消了这一影响(例如,人畜共患病中的布鲁氏菌病:IRR为0.516,95% CI [0.498,0.534],p <0.001;检疫性疾病中的出血热:IRR为0.930,95% CI [0.498,0.534],p <0.001):IRR为0.930,95% CI [0.881,0.981],p = 0.008)。此外,中国中部地区(IRR:1.704,95% CI [1.699,1.708];P <0.001)和东北地区(IRR:1.713,95% CI [1.700,1.726];P <0.001)的总体城乡差异尤为明显。我们研究的一个主要局限是,发病率是根据年平均人口数据计算的,没有考虑人口流动性。结论 我们的研究表明,在儿童、青少年中,应报告传染病的发病率存在明显的城乡差异。城市地区的负担比农村地区高出 2 倍多,而且这种差距似乎还在扩大,尤其是受结核病、猩红热、感染性腹泻和斑疹伤寒的影响。这些研究结果突出表明,迫切需要采取干预措施来减轻传染病的负担,并解决城乡差距日益扩大的问题。
{"title":"Long-term variations of urban–Rural disparities in infectious disease burden of over 8.44 million children, adolescents, and youth in China from 2013 to 2021: An observational study","authors":"Li Chen, Yi Xing, Yi Zhang, Junqing Xie, Binbin Su, Jianuo Jiang, M. Geng, Xiang Ren, Tongjun Guo, W. Yuan, Qi Ma, Manman Chen, M. Cui, Jieyu Liu, Yi Song, Liping Wang, Yanhui Dong, Jun Ma","doi":"10.1371/journal.pmed.1004374","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004374","url":null,"abstract":"Background An accelerated epidemiological transition, spurred by economic development and urbanization, has led to a rapid transformation of the disease spectrum. However, this transition has resulted in a divergent change in the burden of infectious diseases between urban and rural areas. The objective of our study was to evaluate the long-term urban–rural disparities in infectious diseases among children, adolescents, and youths in China, while also examining the specific diseases driving these disparities. Methods and findings This observational study examined data on 43 notifiable infectious diseases from 8,442,956 cases from individuals aged 4 to 24 years, with 4,487,043 cases in urban areas and 3,955,913 in rural areas. The data from 2013 to 2021 were obtained from China’s Notifiable Infectious Disease Surveillance System. The 43 infectious diseases were categorized into 7 categories: vaccine-preventable, bacterial, gastrointestinal and enterovirus, sexually transmitted and bloodborne, vectorborne, zoonotic, and quarantinable diseases. The calculation of infectious disease incidence was stratified by urban and rural areas. We used the index of incidence rate ratio (IRR), calculated by dividing the urban incidence rate by the rural incidence rate for each disease category, to assess the urban–rural disparity. During the nine-year study period, most notifiable infectious diseases in both urban and rural areas exhibited either a decreased or stable pattern. However, a significant and progressively widening urban–rural disparity in notifiable infectious diseases was observed. Children, adolescents, and youths in urban areas experienced a higher average yearly incidence compared to their rural counterparts, with rates of 439 per 100,000 compared to 211 per 100,000, respectively (IRR: 2.078, 95% CI [2.075, 2.081]; p < 0.001). From 2013 to 2021, this disparity was primarily driven by higher incidences of pertussis (IRR: 1.782, 95% CI [1.705, 1.862]; p < 0.001) and seasonal influenza (IRR: 3.213, 95% CI [3.205, 3.220]; p < 0.001) among vaccine-preventable diseases, tuberculosis (IRR: 1.011, 95% CI [1.006, 1.015]; p < 0.001), and scarlet fever (IRR: 2.942, 95% CI [2.918, 2.966]; p < 0.001) among bacterial diseases, infectious diarrhea (IRR: 1.932, 95% CI [1.924, 1.939]; p < 0.001), and hand, foot, and mouth disease (IRR: 2.501, 95% CI [2.491, 2.510]; p < 0.001) among gastrointestinal and enterovirus diseases, dengue (IRR: 11.952, 95% CI [11.313, 12.628]; p < 0.001) among vectorborne diseases, and 4 sexually transmitted and bloodborne diseases (syphilis: IRR 1.743, 95% CI [1.731, 1.755], p < 0.001; gonorrhea: IRR 2.658, 95% CI [2.635, 2.682], p < 0.001; HIV/AIDS: IRR 2.269, 95% CI [2.239, 2.299], p < 0.001; hepatitis C: IRR 1.540, 95% CI [1.506, 1.575], p < 0.001), but was partially offset by lower incidences of most zoonotic and quarantinable diseases in urban areas (for example, brucellosis among zoonotic: IRR 0.516, 95% CI [0.498, 0.534], p < 0.00","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular outcomes 50 years after antenatal exposure to betamethasone: Follow-up of a randomised double-blind, placebo-controlled trial. 产前接触倍他米松 50 年后的心血管后果:随机双盲安慰剂对照试验的后续研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.1371/journal.pmed.1004378
Anthony G B Walters, Greg D Gamble, Caroline A Crowther, Stuart R Dalziel, Carl L Eagleton, Christopher J D McKinlay, Barry J Milne, Jane E Harding

Background: Antenatal corticosteroids for women at risk of preterm birth reduce neonatal morbidity and mortality, but there is limited evidence regarding their effects on long-term health. This study assessed cardiovascular outcomes at 50 years after antenatal exposure to corticosteroids.

Methods and findings: We assessed the adult offspring of women who participated in the first randomised, double-blind, placebo-controlled trial of antenatal betamethasone for the prevention of neonatal respiratory distress syndrome (RDS) (1969 to 1974). The first 717 mothers received 2 intramuscular injections of 12 mg betamethasone or placebo 24 h apart and the subsequent 398 received 2 injections of 24 mg betamethasone or equivalent volume of placebo. Follow-up included a health questionnaire and consent to access administrative data sources. The co-primary outcomes were the prevalence of cardiovascular risk factors (any of hypertension, hyperlipidaemia, diabetes mellitus, gestational diabetes mellitus, or prediabetes) and age at first major adverse cardiovascular event (MACE) (cardiovascular death, myocardial infarction, coronary revascularisation, stroke, admission for peripheral vascular disease, and admission for heart failure). Analyses were adjusted for gestational age at entry, sex, and clustering. Of 1,218 infants born to 1,115 mothers, we followed up 424 (46% of survivors; 212 [50%] female) at mean (standard deviation) age 49.3 (1.0) years. There were no differences between those exposed to betamethasone or placebo for cardiovascular risk factors (159/229 [69.4%] versus 131/195 [67.2%]; adjusted relative risk 1.02, 95% confidence interval [CI] [0.89, 1.18;]; p = 0.735) or age at first MACE (adjusted hazard ratio 0.58, 95% CI [0.23, 1.49]; p = 0.261). There were also no differences in the components of these composite outcomes or in any of the other secondary outcomes. Key limitations were follow-up rate and lack of in-person assessments.

Conclusions: There is no evidence that antenatal corticosteroids increase the prevalence of cardiovascular risk factors or incidence of cardiovascular events up to 50 years of age. Established benefits of antenatal corticosteroids are not outweighed by an increase in adult cardiovascular disease.

背景:对有早产风险的妇女使用产前皮质类固醇可降低新生儿发病率和死亡率,但有关其对长期健康影响的证据却很有限。本研究评估了产前接触皮质类固醇后50年的心血管结果:我们对参加了首例产前倍他米松预防新生儿呼吸窘迫综合征(RDS)随机、双盲、安慰剂对照试验(1969 年至 1974 年)的妇女的成年后代进行了评估。首批 717 名母亲接受了两次 12 毫克倍他米松或安慰剂的肌肉注射,每次间隔 24 小时,随后的 398 名母亲接受了两次 24 毫克倍他米松或等量安慰剂的注射。随访包括健康问卷调查和同意访问管理数据源。共同主要结果是心血管风险因素(任何高血压、高脂血症、糖尿病、妊娠糖尿病或糖尿病前期)的发病率和首次发生重大不良心血管事件(MACE)(心血管死亡、心肌梗死、冠状动脉血运重建、中风、因外周血管疾病入院和因心力衰竭入院)的年龄。分析根据入院时的胎龄、性别和聚类进行了调整。在 1,115 名母亲所生的 1,218 名婴儿中,我们对 424 名婴儿(占存活婴儿的 46%;212 [50%] 名女性)进行了随访,平均(标准差)年龄为 49.3 (1.0)岁。接受倍他米松或安慰剂治疗的患者在心血管风险因素(159/229 [69.4%] 对 131/195 [67.2%];调整后相对风险 1.02,95% 置信区间 [CI] [0.89, 1.18;];P = 0.735)或首次 MACE 的年龄(调整后危险比 0.58,95% CI [0.23, 1.49];P = 0.261)方面没有差异。这些综合结果的组成部分或任何其他次要结果也没有差异。主要的局限性在于随访率和缺乏亲自评估:没有证据表明产前皮质类固醇会增加心血管风险因素的发生率或50岁前心血管事件的发生率。产前皮质类固醇的既定益处不会因成人心血管疾病的增加而被抵消。
{"title":"Cardiovascular outcomes 50 years after antenatal exposure to betamethasone: Follow-up of a randomised double-blind, placebo-controlled trial.","authors":"Anthony G B Walters, Greg D Gamble, Caroline A Crowther, Stuart R Dalziel, Carl L Eagleton, Christopher J D McKinlay, Barry J Milne, Jane E Harding","doi":"10.1371/journal.pmed.1004378","DOIUrl":"10.1371/journal.pmed.1004378","url":null,"abstract":"<p><strong>Background: </strong>Antenatal corticosteroids for women at risk of preterm birth reduce neonatal morbidity and mortality, but there is limited evidence regarding their effects on long-term health. This study assessed cardiovascular outcomes at 50 years after antenatal exposure to corticosteroids.</p><p><strong>Methods and findings: </strong>We assessed the adult offspring of women who participated in the first randomised, double-blind, placebo-controlled trial of antenatal betamethasone for the prevention of neonatal respiratory distress syndrome (RDS) (1969 to 1974). The first 717 mothers received 2 intramuscular injections of 12 mg betamethasone or placebo 24 h apart and the subsequent 398 received 2 injections of 24 mg betamethasone or equivalent volume of placebo. Follow-up included a health questionnaire and consent to access administrative data sources. The co-primary outcomes were the prevalence of cardiovascular risk factors (any of hypertension, hyperlipidaemia, diabetes mellitus, gestational diabetes mellitus, or prediabetes) and age at first major adverse cardiovascular event (MACE) (cardiovascular death, myocardial infarction, coronary revascularisation, stroke, admission for peripheral vascular disease, and admission for heart failure). Analyses were adjusted for gestational age at entry, sex, and clustering. Of 1,218 infants born to 1,115 mothers, we followed up 424 (46% of survivors; 212 [50%] female) at mean (standard deviation) age 49.3 (1.0) years. There were no differences between those exposed to betamethasone or placebo for cardiovascular risk factors (159/229 [69.4%] versus 131/195 [67.2%]; adjusted relative risk 1.02, 95% confidence interval [CI] [0.89, 1.18;]; p = 0.735) or age at first MACE (adjusted hazard ratio 0.58, 95% CI [0.23, 1.49]; p = 0.261). There were also no differences in the components of these composite outcomes or in any of the other secondary outcomes. Key limitations were follow-up rate and lack of in-person assessments.</p><p><strong>Conclusions: </strong>There is no evidence that antenatal corticosteroids increase the prevalence of cardiovascular risk factors or incidence of cardiovascular events up to 50 years of age. Established benefits of antenatal corticosteroids are not outweighed by an increase in adult cardiovascular disease.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11018286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positive affect during adolescence and health and well-being in adulthood: An outcome-wide longitudinal approach 青春期的积极情绪与成年后的健康和幸福:全结果纵向方法
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.1371/journal.pmed.1004365
Eric S Kim, R. Wilkinson, S. Okuzono, Ying Chen, K. Shiba, R. Cowden, T. VanderWeele
Background Several intergovernmental organizations, including the World Health Organization and United Nations, are urging countries to use well-being indicators for policymaking. This trend, coupled with increasing recognition that positive affect is beneficial for health/well-being, opens new avenues for intervening on positive affect to improve outcomes. However, it remains unclear if positive affect in adolescence shapes health/well-being in adulthood. We examined if increases in positive affect during adolescence were associated with better health/well-being in adulthood across 41 outcomes. Methods and findings We conducted a longitudinal cohort study using data from Add Health—a prospective and nationally representative cohort of community-dwelling U.S. adolescents. Using regression models, we evaluated if increases in positive affect over 1 year (between Wave I; 1994 to 1995 and Wave II; 1995 to 1996) were associated with better health/well-being 11.37 years later (in Wave IV; 2008; N = 11,040) or 20.64 years later (in Wave V; 2016 to 2018; N = 9,003). Participants were aged 15.28 years at study onset, and aged 28.17 or 37.20 years—during the final assessment. Participants with the highest (versus lowest) positive affect had better outcomes on 3 (of 13) physical health outcomes (e.g., higher cognition (β = 0·12, 95% CI = 0·05, 0·19, p = 0.002)), 3 (of 9) health behavior outcomes (e.g., lower physical inactivity (RR = 0·80, CI = 0·66, 0·98, p = 0.029)), 6 (of 7) mental health outcomes (e.g., lower anxiety (RR = 0·81, CI = 0·71, 0·93, p = 0.003)), 2 (of 3) psychological well-being (e.g., higher optimism (β = 0·20, 95% CI = 0·12, 0·28, p < 0.001)), 4 (of 7) social outcomes (e.g., lower loneliness (β = −0·09, 95% CI = −0·16, −0·02, p = 0.015)), and 1 (of 2) civic/prosocial outcomes (e.g., more voting (RR = 1·25, 95% CI = 1·16, 1·36, p < 0.001)). Study limitations include potential unmeasured confounding and reverse causality. Conclusions Enhanced positive affect during adolescence is linked with a range of improved health/well-being outcomes in adulthood. These findings suggest the promise of testing scalable positive affect interventions and policies to more definitively assess their impact on outcomes.
背景 一些政府间组织,包括世界卫生组织和联合国,正在敦促各国利用福祉指标进行决策。这一趋势,加上越来越多的人认识到积极情感有利于健康/幸福,为干预积极情感以改善结果开辟了新的途径。然而,青少年时期的积极情绪是否会影响成年后的健康/福祉,目前仍不清楚。我们研究了青春期积极情绪的增加是否与成年后更好的健康/福祉相关,共涉及 41 项结果。方法和研究结果 我们利用 Add Health 的数据进行了一项纵向队列研究--Add Health 是一项对居住在社区的美国青少年进行的具有全国代表性的前瞻性队列研究。通过回归模型,我们评估了一年内积极情绪的增加(第一波,1994 年至 1995 年和第二波,1995 年至 1996 年之间)是否与 11.37 年后(第四波,2008 年;N = 11,040 人)或 20.64 年后(第五波,2016 年至 2018 年;N = 9,003 人)更好的健康/福祉相关。参与者在研究开始时的年龄为 15.28 岁,在最终评估时的年龄为 28.17 岁或 37.20 岁。较低的焦虑(RR = 0-81,CI = 0-71,0-93,p = 0.003)),2 个(共 3 个)心理健康结果(例如,较高的乐观度(β = 0-20,95% CI = 0-12,0-28,p < 0.001)),4 个(共 7 个)社会结果(例如,较低的孤独感(β = 0-80,CI = 0-66,0-98,p = 0.029))、降低孤独感(β = -0-09,95% CI = -0-16,-0-02,p = 0.015)),以及 1 项(共 2 项)公民/前社会结果(例如,更多投票(RR = 1-25,95% CI = 1-16,1-36,p < 0.001))。研究的局限性包括潜在的未测量混杂因素和反向因果关系。结论 青少年时期积极情绪的增强与成年后一系列健康/福利状况的改善有关。这些研究结果表明,有希望对可扩展的积极情感干预措施和政策进行测试,以更明确地评估其对结果的影响。
{"title":"Positive affect during adolescence and health and well-being in adulthood: An outcome-wide longitudinal approach","authors":"Eric S Kim, R. Wilkinson, S. Okuzono, Ying Chen, K. Shiba, R. Cowden, T. VanderWeele","doi":"10.1371/journal.pmed.1004365","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004365","url":null,"abstract":"Background Several intergovernmental organizations, including the World Health Organization and United Nations, are urging countries to use well-being indicators for policymaking. This trend, coupled with increasing recognition that positive affect is beneficial for health/well-being, opens new avenues for intervening on positive affect to improve outcomes. However, it remains unclear if positive affect in adolescence shapes health/well-being in adulthood. We examined if increases in positive affect during adolescence were associated with better health/well-being in adulthood across 41 outcomes. Methods and findings We conducted a longitudinal cohort study using data from Add Health—a prospective and nationally representative cohort of community-dwelling U.S. adolescents. Using regression models, we evaluated if increases in positive affect over 1 year (between Wave I; 1994 to 1995 and Wave II; 1995 to 1996) were associated with better health/well-being 11.37 years later (in Wave IV; 2008; N = 11,040) or 20.64 years later (in Wave V; 2016 to 2018; N = 9,003). Participants were aged 15.28 years at study onset, and aged 28.17 or 37.20 years—during the final assessment. Participants with the highest (versus lowest) positive affect had better outcomes on 3 (of 13) physical health outcomes (e.g., higher cognition (β = 0·12, 95% CI = 0·05, 0·19, p = 0.002)), 3 (of 9) health behavior outcomes (e.g., lower physical inactivity (RR = 0·80, CI = 0·66, 0·98, p = 0.029)), 6 (of 7) mental health outcomes (e.g., lower anxiety (RR = 0·81, CI = 0·71, 0·93, p = 0.003)), 2 (of 3) psychological well-being (e.g., higher optimism (β = 0·20, 95% CI = 0·12, 0·28, p < 0.001)), 4 (of 7) social outcomes (e.g., lower loneliness (β = −0·09, 95% CI = −0·16, −0·02, p = 0.015)), and 1 (of 2) civic/prosocial outcomes (e.g., more voting (RR = 1·25, 95% CI = 1·16, 1·36, p < 0.001)). Study limitations include potential unmeasured confounding and reverse causality. Conclusions Enhanced positive affect during adolescence is linked with a range of improved health/well-being outcomes in adulthood. These findings suggest the promise of testing scalable positive affect interventions and policies to more definitively assess their impact on outcomes.","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140780921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Socioeconomic and ethnic disparities associated with access to cochlear implantation for severe-to-profound hearing loss: A multicentre observational study of UK adults 与接受人工耳蜗植入治疗重度至永久性听力损失有关的社会经济和种族差异:英国成人多中心观察研究
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.1371/journal.pmed.1004296
C. Swords, Reshma Ghedia, Hannah Blanchford, James Arwyn-Jones, E. Heward, K. Milinis, J. Hardman, Matthew E Smith, Manohar Bance, Jameel Muzaffar
Background Patients with severe-to-profound hearing loss may benefit from management with cochlear implants. These patients need a referral to a cochlear implant team for further assessment and possible surgery. The referral pathway may result in varied access to hearing healthcare. This study aimed to explore referral patterns and whether there were any socioeconomic or ethnic associations with the likelihood of referral. The primary outcome was to determine factors influencing referral for implant assessment. The secondary outcome was to identify factors impacting whether healthcare professionals had discussed the option of referral. Methods and findings A multicentre multidisciplinary observational study was conducted in secondary care Otolaryngology and Audiology units in Great Britain. Adults fulfilling NICE (2019) audiometric criteria for implant assessment were identified over a 6-month period between 1 July and 31 December 2021. Patient- and site-specific characteristics were extracted. Multivariable binary logistic regression was employed to compare a range of factors influencing the likelihood of implant discussion and referral including patient-specific (demographics, past medical history, and degree of hearing loss) and site-specific factors (cochlear implant champion and whether the hospital performed implants). Hospitals across all 4 devolved nations of the UK were invited to participate, with data submitted from 36 urban hospitals across England, Scotland, and Wales. Nine hospitals (25%) conducted cochlear implant assessments. The majority of patients lived in England (n = 5,587, 86.2%); the rest lived in Wales (n = 419, 6.5%) and Scotland (n = 233, 3.6%). The mean patient age was 72 ± 19 years (mean ± standard deviation); 54% were male, and 75·3% of participants were white, 6·3% were Asian, 1·5% were black, 0·05% were mixed, and 4·6% were self-defined as a different ethnicity. Of 6,482 submitted patients meeting pure tone audiometric thresholds for cochlear implantation, 311 already had a cochlear implant. Of the remaining 6,171, 35.7% were informed they were eligible for an implant, but only 9.7% were referred for assessment. When adjusted for site- and patient-specific factors, stand-out findings included that adults were less likely to be referred if they lived in more deprived area decile within Indices of Multiple Deprivation (4th (odds ratio (OR): 2·19; 95% confidence interval (CI): [1·31, 3·66]; p = 0·002), 5th (2·02; [1·21, 3·38]; p = 0·05), 6th (2·32; [1·41, 3·83]; p = 0.05), and 8th (2·07; [1·25, 3·42]; p = 0·004)), lived in London (0·40; [0·29, 0·57]; p < 0·001), were male (females 1·52; [1·27, 1·81]; p < 0·001), or were older (0·97; [0·96, 0·97]; p < 0·001). They were less likely to be informed of their potential eligibility if they lived in more deprived areas (4th (1·99; [1·49, 2·66]; p < 0·001), 5th (1·75; [1·31, 2·33], p < 0·001), 6th (1·85; [1·39, 2·45]; p < 0·001), 7th (1·66; [1·25, 2·21]; p < 0·001), and 8th (1·
背景重度到永久性听力损失患者可能会受益于人工耳蜗的治疗。这些患者需要转诊到人工耳蜗植入团队接受进一步评估,并可能接受手术治疗。转诊途径可能会导致患者获得听力保健的机会不同。本研究旨在探讨转诊模式,以及转诊的可能性是否与社会经济或种族有关。主要结果是确定影响转诊进行植入评估的因素。次要结果是确定影响医护人员是否讨论过转诊选择的因素。方法和结果 在英国的二级医疗耳鼻喉科和听力科进行了一项多中心多学科观察研究。在 2021 年 7 月 1 日至 12 月 31 日的 6 个月期间,对符合 NICE(2019 年)听力测定标准的成人进行了植入评估。提取了患者和特定场所的特征。采用多变量二元逻辑回归来比较影响植入讨论和转诊可能性的一系列因素,包括患者特异性因素(人口统计学、既往病史和听力损失程度)和医院特异性因素(人工耳蜗植入冠军和医院是否进行过植入)。英国所有 4 个分权国家的医院均受邀参与,英格兰、苏格兰和威尔士的 36 家城市医院提交了数据。九家医院(25%)进行了人工耳蜗植入评估。大部分患者居住在英格兰(5,587 人,86.2%),其余患者居住在威尔士(419 人,6.5%)和苏格兰(233 人,3.6%)。患者平均年龄为 72 ± 19 岁(平均 ± 标准差);54% 为男性,75-3% 的参与者为白人,6-3% 为亚裔,1-5% 为黑人,0-05% 为混血,4-6% 自定义为不同种族。在提交的 6482 名符合人工耳蜗植入纯音测听阈值的患者中,有 311 人已经植入了人工耳蜗。在剩余的 6171 名患者中,有 35.7% 的人被告知符合植入条件,但只有 9.7% 的人被转介接受评估。在对地点和患者的特定因素进行调整后,突出的发现包括:如果成年人居住在多重贫困指数中较贫困的十分位数(第 4 位(几率比(OR):2-19;95% 置信区间(CI):[1-31, 3-66];P = 0-002)、第 5 位(2-02;[1-21, 3-38];P = 0-05)、第 6 位(2-32;[1-41, 3-83];P = 0.0-004)、住在伦敦(0-40;[0-29,0-57];p < 0-001)、男性(女性 1-52;[1-27,1-81];p < 0-001)或年龄较大(0-97;[0-96,0-97];p < 0-001)。如果他们居住在较为贫困的地区,那么他们被告知自己可能符合条件的可能性较低(第 4 位 (1-99; [1-49, 2-66]; p < 0-001)、第 5 位 (1-75; [1-31, 2-33]; p < 0-001)、第 6 位 (1-85;1-85; [1-39, 2-45]; p < 0-001)、第 7(1-66; [1-25, 2-21];p < 0-001)和第 8(1-74; [1-31, 2-31];p < 0-001)十分位数)、英格兰北部或伦敦(北 0-74;0-74;[0-62,0-89];p = 0-001;伦敦 0-44;[0-35,0-56];p < 0-001),与白人患者相比,亚裔或黑人患者(亚裔 0-58;[0-43,0-79];p<0-001;黑人 0-56;[0-34,0-92];p = 0-021)、男性(女性 1-46;[1-31,1-62];p<0-001)或年龄较大(0-98;[0-98,0-98];p<0-001)。研究方法的局限性在于其观察性质、对转诊服务准确记录的依赖性以及某些人口群体的代表性可能不足。结论 目前,大多数符合人工耳蜗植入纯音听阈标准的成年人并未被适当转诊进行评估。有必要针对代表性不足的患者群体提高转诊率。未来的研究应让利益相关者参与进来,共同探讨造成这种差异的原因。实施直接的措施,如教育措施和即时识别的自动弹出工具,有助于简化转诊流程。
{"title":"Socioeconomic and ethnic disparities associated with access to cochlear implantation for severe-to-profound hearing loss: A multicentre observational study of UK adults","authors":"C. Swords, Reshma Ghedia, Hannah Blanchford, James Arwyn-Jones, E. Heward, K. Milinis, J. Hardman, Matthew E Smith, Manohar Bance, Jameel Muzaffar","doi":"10.1371/journal.pmed.1004296","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004296","url":null,"abstract":"Background Patients with severe-to-profound hearing loss may benefit from management with cochlear implants. These patients need a referral to a cochlear implant team for further assessment and possible surgery. The referral pathway may result in varied access to hearing healthcare. This study aimed to explore referral patterns and whether there were any socioeconomic or ethnic associations with the likelihood of referral. The primary outcome was to determine factors influencing referral for implant assessment. The secondary outcome was to identify factors impacting whether healthcare professionals had discussed the option of referral. Methods and findings A multicentre multidisciplinary observational study was conducted in secondary care Otolaryngology and Audiology units in Great Britain. Adults fulfilling NICE (2019) audiometric criteria for implant assessment were identified over a 6-month period between 1 July and 31 December 2021. Patient- and site-specific characteristics were extracted. Multivariable binary logistic regression was employed to compare a range of factors influencing the likelihood of implant discussion and referral including patient-specific (demographics, past medical history, and degree of hearing loss) and site-specific factors (cochlear implant champion and whether the hospital performed implants). Hospitals across all 4 devolved nations of the UK were invited to participate, with data submitted from 36 urban hospitals across England, Scotland, and Wales. Nine hospitals (25%) conducted cochlear implant assessments. The majority of patients lived in England (n = 5,587, 86.2%); the rest lived in Wales (n = 419, 6.5%) and Scotland (n = 233, 3.6%). The mean patient age was 72 ± 19 years (mean ± standard deviation); 54% were male, and 75·3% of participants were white, 6·3% were Asian, 1·5% were black, 0·05% were mixed, and 4·6% were self-defined as a different ethnicity. Of 6,482 submitted patients meeting pure tone audiometric thresholds for cochlear implantation, 311 already had a cochlear implant. Of the remaining 6,171, 35.7% were informed they were eligible for an implant, but only 9.7% were referred for assessment. When adjusted for site- and patient-specific factors, stand-out findings included that adults were less likely to be referred if they lived in more deprived area decile within Indices of Multiple Deprivation (4th (odds ratio (OR): 2·19; 95% confidence interval (CI): [1·31, 3·66]; p = 0·002), 5th (2·02; [1·21, 3·38]; p = 0·05), 6th (2·32; [1·41, 3·83]; p = 0.05), and 8th (2·07; [1·25, 3·42]; p = 0·004)), lived in London (0·40; [0·29, 0·57]; p < 0·001), were male (females 1·52; [1·27, 1·81]; p < 0·001), or were older (0·97; [0·96, 0·97]; p < 0·001). They were less likely to be informed of their potential eligibility if they lived in more deprived areas (4th (1·99; [1·49, 2·66]; p < 0·001), 5th (1·75; [1·31, 2·33], p < 0·001), 6th (1·85; [1·39, 2·45]; p < 0·001), 7th (1·66; [1·25, 2·21]; p < 0·001), and 8th (1·","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140756907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PLoS Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1